Compare NODK & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NODK | ALXO |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.8M | 240.8M |
| IPO Year | 2016 | 2020 |
| Metric | NODK | ALXO |
|---|---|---|
| Price | $13.93 | $2.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 11.6K | ★ 906.5K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $285,050,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.02 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.11 | $0.41 |
| 52 Week High | $14.70 | $2.66 |
| Indicator | NODK | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 68.61 | 58.24 |
| Support Level | $13.03 | $1.99 |
| Resistance Level | $14.34 | $2.30 |
| Average True Range (ATR) | 0.27 | 0.17 |
| MACD | 0.11 | 0.04 |
| Stochastic Oscillator | 90.24 | 77.95 |
NI Holdings Inc is a stockholding company. Through its subsidiaries, the company operates in the insurance industry, offering homeowners and farmowners insurance policies, crop insurance policies, home insurance policies, etc. These insurance products are distributed through a network of exclusive and independent agents across the United States. The group's reportable segments are: Private Passenger Auto, Non-Standard Auto, Home and Farm, Crop, and All Other (which mainly consists of commercial, assumed reinsurance, and its excess liability business). Maximum revenue is generated from the Home and Farm segment.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.